Table 2: ADMSCs’ effects on renal function and tissue oxidative stress markers level in cisplatin- induced nephrotoxicity on long term. (mean ± SD).

	Control	Cisplatin	Cisplatin+CMedium	Cisplatin+ SCs
S. Creatinlne(mg/dl)
Day 4	0.47±0.11	1.92±0.04*	1.89i0.12*	1.02±0.11*°
Day 7	0.48±0.13	1.61±0.06*‡	1.62±0.04*‡	0.85±0.11*°‡
Day 11	0.48±0.18	0.97±0.14*‡†	0.98±0.18*‡†	0.70±0.08*°‡
Day 30	0.43±0.11	0.76±0.04*‡†	0.79±0.05*‡†	0.56±0.07*°‡†
O.Clearance(ml/min./100gm)
Day 4	1.600±0.860	0.007±0.002*	0.008±0.002*	0.017±0.009*°
Day 7	1.600±0.760	0.014±0.001*‡	0.012±0.003*‡	0.045±0.012*°‡
Day 11	1.600±0.790	0.054±0.016*‡†	0.056±0.020*‡†	0.650±0.117*°‡†
Day 30	1.600±0.350	0.340±0.240*‡†•	0.360±0.320*‡†•	0.860±0.243*°‡†
S.BUN(mg/dl)
Day 4	054.36±03.31	266.70±08.70*	265.30±08.60*	097.80±07.67*°
Day 7	053.39±04.51	228.70±l8.00*‡	236.00±l5.00*‡	076.40±04.30*‡
Day 11	054.43±03.91	137.40±14.70*‡†	138.60±l6.30*‡†	068.34±04.60*°‡†
Day 30	054.55±03.62	111.46±11.50*‡†•	112.58±08.40*‡†•	068.34±04.60*°‡†
MDA tissue (nmol/gm)
Day 4	14.50±3.43	67.40±3.40*	69.50±4.80*	34.20±8.54*°
Day 7	14.50±3.89	65.10±4.54*	63.20±3.87*	25.40±2.86*°‡
Day 11	14.60±2.56	34.10±4.70*‡†	37.20±4.60*‡†	17.30±3.82°‡†
Day 30	14.50±2.46	32.80±5.10*‡†	33.20±5.40*‡†	16.32±3.65°‡†
Tissue GSH (mmol/gm)
Day 4	5.36±0.17	0.26±0.03*	0.27±0.05*	0.77±0.03*°
Day 7	5.38±1.15	0.53±0.04*‡	0.56±0.05*‡	2.56±0.05*°‡
Day 11	5.35±0.18	1.38±0.42*‡†	1.35±0.35*‡†	3.53±0.21*°‡†
Day 30	5.39±0.35	1.92±0.04*‡†•	1.95±0.08*‡†•	4.12±0.22*°‡†•
Tissue SOD U/gm)
Day 4	20.86±1.24	3.25±0.64*	3.70±0.65*	6.85±0.52*°
Day 7	20.82±1.64	6.24±0.57*‡	6.46±0.62*‡	10.67±0.38*°‡
Day 11	20.78±1.28	9.96±0.30*‡†	9.94±0.52*‡†	15.62±0.43*°‡†
Day 30	20.73±0.84	15.24±0.46*‡†•	15.43±0.52*‡†•	18.67±0.42*°‡†•

Significant difference compared to corresponding Significant * control, ^° cisplatin groups

Significant difference compared to intra-group day4^‡, day7^†, day11^• by Kruskal-Wallis test at P≤0.05